Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 229

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients

Open access
Sim, Geok Choo, Martin-Orozco, Natalia, Jin, Lei, Yang, Yan, Wu, Sheng, Washington, Edwina, Sanders, Deborah, Lacey, Carol, Wang, Yijun, Vence, Luis, Hwu, Patrick, Radvanyi, Laszlo·2014·Journal of Clinical Investigation

Abstract

High-dose (HD) IL-2 therapy in patients with cancer increases the general population of Tregs, which are positive for CD4, CD25, and the Treg-specific marker Foxp3. It is unknown whether specific subsets of Tregs are activated and expanded during HD IL-2 therapy or whether activation of any particular Treg subset correlates with clinical outcome. Here, we evaluated Treg population subsets that were induced in patients with melanoma following HD IL-2 therapy. We identified a Treg population that was positive for CD4, CD25, Foxp3, and the inducible T cell costimulator (ICOS). This Treg population increased more than any other lymphocyte subset during HD IL-2 therapy and had an activated Treg phenotype, as indicated by high levels of CD39, CD73, and TGF-β. ICOS(+) Tregs were the most proliferative lymphocyte population in the blood after IL-2 therapy. Patients with melanoma with enhanced expansion of ICOS(+) Tregs in blood following the first cycle of HD IL-2 therapy had worse clinical outcomes than patients with fewer ICOS(+) Tregs. However, there was no difference in total Treg expansion between HD IL-2 responders and nonresponders. These data suggest that increased expansion of the ICOS(+) Treg population following the first cycle of HD IL-2 therapy may be predictive of clinical outcome.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1172/jci46266

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 229

Metadata

Authors
Sim, G. C., Martin-Orozco, N., Jin, L., Yang, Y., Wu, S., Washington, E., Sanders, D., Lacey, C., Wang, Y., Vence, L., Hwu, P., & Radvanyi, L.
Venue
Journal of Clinical Investigation
Published
2013-12-02
Volume
124
Issue
1
Pages
99-110
ISSN
0021-9738 (ISSN-L)
OpenAlex
W2164992400
Cited by
229
References
5
FWCI
9.60
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. https://app.cochat.ai/papers/10.1172/jci46266
The paper
Sim, G. C., Martin-Orozco, N., Jin, L., Yang, Y., Wu, S., Washington, E., Sanders, D., Lacey, C., Wang, Y., Vence, L., Hwu, P., & Radvanyi, L. (2014). IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. Journal of Clinical Investigation. https://doi.org/10.1172/jci46266

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.